hotspot -WSS

hotspot

author：leisure time 2025-09-30 03:50:12 Page View：9113

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approves world's first CRISPR
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Adam's Biotech Scorecard: Do Sarepta's exon

ThisistheonlineeditionofAdam’sBiotechScorecard,asubscriber-onlynewsletter.STAT+subscriberscansignuph

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

In diabetes hearing, Sanders takes on a new foe: food makers

Sen.BerneSanders(I-Vt.)KevinDietsch/GettyImagesWASHINGTON—Sen.BernieSanders(I-Vt.)hasanewcorporateta

hotspot

explore

leisure time

In diabetes hearing, Sanders takes on a new foe: food makers